Looking at second treatments for advanced lung cancer after immunotherapy stops working

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced lung cancer (NSCLC) whose disease got worse after first-line treatment with an immune checkpoint inhibitor drug. It observes the treatments they received afterwards.

Age

The record gives a minimum age of 1 Year and no upper limit.

Sex

All sexes can join.

Disease stage

Locally advanced or metastatic NSCLC that cannot be cured, confirmed by tissue or cell examination (8th edition AJCC staging).

Earlier treatment

Must have had first-line treatment based on an immune checkpoint inhibitor drug, with disease progression recorded during it. More than 2 cycles of that treatment.

Main reasons for not taking part

• First-line immune checkpoint inhibitor treatment of 2 cycles or fewer
• Incomplete key baseline and treatment information
• Incomplete clinical and pathological data (such as age, gender, smoking history, tumor location)
• Other factors the investigator thinks could affect the results or end participation early

The registry criteria, word for word

What the trial wants to find out

The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns. It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies. Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence. This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.

The group in the trial

• Observation

  Patients with advanced NSCLC who have received standard first-line immune checkpoint inhibitor therapy and have experienced disease progression. Retrospective case screening and collection were conducted, and follow-up observations were carried out.